crizotinib
Xcovery Holdings Seeking FDA Approval for Frontline Ensartinib in ALK-Positive NSCLC
The firm filed a new drug application with the FDA for its ALK inhibitor ensartinib, which is already approved for advanced ALK-positive NSCLC in China.
FDA Approves BMS's Augtyro for Advanced ROS1-Positive NSCLC
The approval is based on results from the Phase I/II TRIDENT-1 clinical trial of Augtyro in both TKI-pretreated and TKI-naïve ROS1-positive NSCLC.
Pfizer Oncology Revenues Fall 4 Percent in Q2; Officials Highlight Encouraging Data From Trials
Executives said the firm's acquisition of Seagen and advancement of new breast cancer candidates will help refocus its efforts in oncology.
Pfizer saw revenue declines in several oncology products, including the CDK4/6 inhibitor Ibrance, the ALK inhibitor Xalkori, and the BRAF inhibitor Braftovi.
The firm's newer precision oncology drugs, including Lorbrena, Braftovi, and Mektovi, however, continued their sales growth in Q3.